[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
[HTML][HTML] Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5
Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …
become dominant in the United States and South Africa, respectively,. These new …
[HTML][HTML] BA. 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage 1. The receptor …
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage 1. The receptor …
[HTML][HTML] Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …
[HTML][HTML] An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
[HTML][HTML] Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
D Planas, N Saunders, P Maes, F Guivel-Benhassine… - Nature, 2022 - nature.com
Abstract The SARS-CoV-2 Omicron variant was first identified in November 2021 in
Botswana and South Africa,–. It has since spread to many countries and is expected to …
Botswana and South Africa,–. It has since spread to many countries and is expected to …
[HTML][HTML] Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …
southern Africa, but its subsequent spread has been extensive, both regionally and globally …
[PDF][PDF] The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
M Hoffmann, N Krüger, S Schulz, A Cossmann… - Cell, 2022 - cell.com
The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become
globally dominant. Further, the high number of mutations in the viral spike protein raised …
globally dominant. Further, the high number of mutations in the viral spike protein raised …
[HTML][HTML] mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the
globe. This new variant of concern carries an unusually high number of mutations in key …
globe. This new variant of concern carries an unusually high number of mutations in key …